Telitacicept · RC18

What is Telitacicept?

Telitacicept is a fusion protein of the TACI extracellular domain fused to an Fc domain. It binds BAFF and APRIL, inhibiting their interactions with B-cell receptors TACI, BCMA, and BAFF-R, thereby suppressing B-cell proliferation and autoimmune responses. It is studied in generalized myasthenia gravis, IgA nephropathy, complement 3 glomerulopathy, and immune complex membranoproliferative glomerulonephritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

RC18

Drug type

Fusion protein

Targets

BAFF (TNFSF13B), APRIL (TNFSF13), BCMA (TNFRSF17) (secondary target), BAFF-R (TNFRSF13C) (secondary target)

Mechanism

Antagonist of BAFF (TNFSF13B) and APRIL (TNFSF13)

Pathways

B-cell proliferation and maturation, B-cell survival

Therapy area

Immunology, Renal & urology

Developer

RemeGen Co., Ltd.

In trials of

ADRX, VOR

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 3

UNII

1FHM3D7Z49

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Complement 3 Glomerulopathy (C3G)Generalized Myasthenia GravisIC-MPGNImmunoglobulin A Nephropathy (IgAN)

Other drugs acting on TNFSF13B / TNFSF13

Sources

• NCI Thesaurus

Updated Oct 3, 2026.